12:00 AM
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Velcade bortezomib: Additional Phase I/II data

Additional data from the Phase I/II VERTICAL trial in 15 evaluable patients showed that Velcade plus Treanda bendamustine and Rituxan rituximab produced 8 complete responses and 4 partial responses. Data were presented at the American Society of Clinical Oncology meeting in Orlando. Last month, Takeda reported safety data...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >